California drug maker Gilead Sciences Inc., which has operations in Branford, said Wednesday it signed a multiyear research collaboration with Yale School of Medicine, focusing on potential cancer treatments, The Associated Press reports.
The Foster City, Calif., biopharmaceutical company will provide $40 million in research support and basic science infrastructure development during the initial four-year period, and will provide a total of up to an additional $100 million over 10 years if an option to renew the collaboration is exercised.
Gilead, which sells HIV treatments such as Atripla and Truvada, will have the first option to license Yale inventions that result from the collaboration.
